169 related articles for article (PubMed ID: 26784680)
1. Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention.
Yıldırım F; Kara İ; Okuyan H; Abacı A; Türkoğlu M; Aygencel G
Clin Respir J; 2017 Nov; 11(6):1071-1073. PubMed ID: 26784680
[TBL] [Abstract][Full Text] [Related]
2. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
[TBL] [Abstract][Full Text] [Related]
3. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Baber U; Dangas G; Cohen DJ; Gibson CM; Mehta SR; Angiolillo DJ; Pocock SJ; Krucoff MW; Kastrati A; Ohman EM; Steg PG; Badimon J; Zafar MU; Chandrasekhar J; Sartori S; Aquino M; Mehran R
Am Heart J; 2016 Dec; 182():125-134. PubMed ID: 27914492
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
6. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Parker WA; Storey RF
Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
[TBL] [Abstract][Full Text] [Related]
7. Diffuse alveolar hemorrhage as a complication of dual antiplatelet therapy for acute coronary syndrome.
Ikeda M; Tanaka H; Sadamatsu K
Cardiovasc Revasc Med; 2011; 12(6):407-11. PubMed ID: 21514251
[TBL] [Abstract][Full Text] [Related]
8. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
Paravattil B; Elewa H
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor: a review of its use in adults with acute coronary syndromes.
Dhillon S
Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
[TBL] [Abstract][Full Text] [Related]
12. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
[TBL] [Abstract][Full Text] [Related]
13. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Vranckx P; Valgimigli M; Windecker S; Steg PG; Hamm C; Jüni P; Garcia-Garcia HM; van Es GA; Serruys PW
EuroIntervention; 2016 Nov; 12(10):1239-1245. PubMed ID: 26606735
[TBL] [Abstract][Full Text] [Related]
14. Bleeding versus thrombosis: role of short DAPT in complex lesions.
Calcagno S; Lucisano L; Mancone M; Cavallo E; Pennacchi M; Stio RE; Sardella G
Minerva Cardioangiol; 2015 Dec; 63(6):533-46. PubMed ID: 26334115
[TBL] [Abstract][Full Text] [Related]
15. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
[TBL] [Abstract][Full Text] [Related]
18. Should all stent patients have prolonged dual antiplatelet therapy?
Kirtane AJ; King SB
JACC Cardiovasc Interv; 2015 May; 8(6):873-875. PubMed ID: 25999115
[No Abstract] [Full Text] [Related]
19. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
20. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]